Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
6-Hydroxymethylacylfulvene in Treating Patients With Stage IVB or Recurrent Cervical Cancer
This study has been completed.
Sponsored by: | National Cancer Institute (NCI) Memorial Sloan-Kettering Cancer Center
|
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of 6-hydroxymethylacylfulvene in treating patients who have stage IVB or recurrent cervical cancer.
Condition | Treatment or Intervention | Phase |
---|---|---|
recurrent cervical cancer cervical adenocarcinoma cervical squamous cell carcinoma cervical adenosquamous cell carcinoma stage IVB cervical cancer |
Drug: -hydroxymethylacylfulvene |
Phase II |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Cervical Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of 6-Hydroxymethylacylfulvene (MGI-114) in Patients With Stage IVB or Recurrent Cervical Carcinoma
OBJECTIVES: I. Evaluate the efficacy of 6-hydroxymethylacylfulvene in patients with stage IVB or recurrent cervical carcinoma.
II. Determine the safety of this drug in this patient population.
PROTOCOL OUTLINE: Patients receive 6-hydroxymethylacylfulvene IV over 5 minutes daily for 5 consecutive days. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.
PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-19 months.
Eligibility
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
Location Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |